UPMC Cancer Center researchers have recently found an interesting connection between immunotherapy drugs. Researchers at the UPMC Hillman Cancer Center in Pittsburgh are looking positively at an immune inhibitor, durvalumab. According to the story, this inhibitor can help improve the survival rate of people suffering from non-small cell, metastatic lung cancer.
As this in-depth research was published in the medical journal Lancet, the Medical News Today team contacted them. The intention was to find out more about the findings. The paper’s senior author gave some insights from her conversation with the team.
Early Results Promises A New Phase In The Research Of Cancer Cure
Liza Villaruz and her colleagues where the primary medical team conducting the research. It was a two phrase trial among 50 people in the experimental group. That is, they are suffering from advanced or metastatic NSCLC.
The research was a 12-month long process where the inhibitory drug containing durvalumab was given to the experiment subjects. The dose was intravenous, which means they all had it once a month for a year.
Viallruz didn’t mention any particular focus group to contradict the experiment results for the experimental one but is confident about the promises it brings.
The survival rate for PD-L1 tumor was six months, and for PD-L1, survived for 11 months, which is a number much greater than that of platinum doublet chemotherapy.
“I believe this contributes to the expanding research on the effectiveness of FDA-approved treatments. It adds to previous studies and is just the beginning. When introducing new therapies in lung cancer, it’s crucial to assess their suitability for real-world situations, ensuring safe administration to patients with borderline performance status.” Said Liza Villaruz in her final statement.
Read Also:
